NA
GENE

NewEdge Advisors’s Genetic Technologies Ltd. GENE Stock Holding History

NewEdge Advisors’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25
Closed -$116 – 4265
2022
Q4 		$116 Buy
+25
New +$142 ﹤0.01% 3355

Other funds holding GENE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
SA
Scarborough Advisors Annapolis, Maryland $914M AUM 17.4% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NewEdge Advisors's GENE Position: Q1 2023 in Review

NewEdge Advisors sold out of Genetic Technologies Ltd. (GENE) in Q1 2023, closing a stake of 25 shares — an estimated $116 sold.

NewEdge Advisors first reported a position in GENE in Q4 2022 and held it in 1 quarter. The position peaked at $116 in Q4 2022. 12 funds tracked by Wall St. Rank hold GENE as of Q1 2023.

  • NewEdge Advisors reported no remaining Genetic Technologies Ltd. position as of Q1 2023 after selling out during the quarter.
  • NewEdge Advisors sold 25 Genetic Technologies Ltd. shares in Q1 2023, an estimated $116.
  • NewEdge Advisors first reported a position in Genetic Technologies Ltd. in Q4 2022 and held it in 1 quarter.
  • NewEdge Advisors's Genetic Technologies Ltd. position peaked at $116 in Q4 2022.
  • 12 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.